Included in the formulation
АТХ:V.04.C.X Other diagnostic preparations
Pharmacodynamics:In the infrared region at 800 nm in blood and plasma has a maximum absorption. With a fluorescence measurement of 830 nm, the emission maximum. With these characteristics, the optical density of the reduced hemoglobin and oxyhemoglobin is almost equal. This allows you to determine the concentration of the drug, both in arterial and venous blood.
Pharmacokinetics:After intravenous administration, it quickly binds to plasma proteins. Up to 95% of the drug is transferred with β-apolipoprotein B.
Not exposed to metabolism.
The half-life in the first phase is 3-4 minutes, in the second - 60-80 minutes. Elimination by the kidneys.
Indications:It is used for the diagnosis of circulatory disorders: measurement of cardiac output and stroke volume, cerebral blood flow, volume of circulating blood; in the diagnosis of liver function - to measure excretory function and blood flow; in ophthalmological angiography - to measure blood flow in the choroid of the eye.
XXI.Z00-Z13.Z03 Medical surveillance and evaluation in case of suspected disease or pathological condition
Contraindications:Hyperthyroidism, autonomic adenoma of the thyroid gland, hyperbilirubinemia in premature and newborns, individual intolerance.
Carefully:Renal insufficiency, hypersensitivity to iodine, patients taking beta-blockers.
Pregnancy and lactation:Recommendations for FDA - category is not defined. It is used during pregnancy and lactation in those cases when the expected effect exceeds the risk for the fetus and the baby.
Dosing and Administration:Use in children
Up to the age of two years: 1.25 mg / kg;
2-11 years: 2.5 mg / kg.
Adults
Intravenous: to diagnose microcirculation - 0.1-0.3 mg / kg; at diagnostics of functions of a liver - 0,25-0,5 mg / kg, in ophthalmic practice - on 0,1-0,3 mg / kg of body weight.
The highest daily dose: 5 mg / kg.
The highest single dose: 5 mg / kg.
Side effects:Eosinophilia, allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Probenecid reduces the excretion of indocyanine green.
Reduce the absorption of drugs containing sodium bisulfite, including, in combination with heparin.
Can reduce absorption: morphine, methadone, trimeridine and other narcotic analgesics, bisulfites, haloperidol, phenobarbital, metamizol sodium, phenylbutazone, anticonvulsants.
Increase absorption: probenecid, rifampicin, cyclopropane.
Special instructions:When mixed with any solvents, in addition to distilled water, precipitation occurs.
When the drug is administered, it should be avoided in the surrounding tissues.